Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
INNV Stock Forecast 2025-2026
$5.03
Current Price
$682.48M
Market Cap
Buy 0
Hold 2
Sell 1
Wall St Analyst Ratings
Distance to INNV Price Targets
-0.6%
To High Target of $5.00
-0.6%
To Median Target of $5.00
-0.6%
To Low Target of $5.00
INNV Price Momentum
-4.7%
1 Week Change
-4.9%
1 Month Change
+5.0%
1 Year Change
+28.0%
Year-to-Date Change
-19.6%
From 52W High of $6.26
+93.5%
From 52W Low of $2.60
📊 TOP ANALYST CALLS
Did INNV Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Innovus Pharmaceuticals is one of their latest high-conviction picks.
Latest INNV Stock Price Targets & Analyst Predictions
Based on our analysis of 10 Wall Street analysts, INNV has a neutral consensus with a median price target of $5.00 (ranging from $5.00 to $5.00). The overall analyst rating is Hold (5.3/10). Currently trading at $5.03, the median forecast implies a -0.6% downside. This outlook is supported by 0 Buy, 2 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Benjamin Rossi at JP Morgan, projecting a 0.6% downside. Conversely, the most conservative target is provided by Benjamin Rossi at JP Morgan, suggesting a 0.6% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
INNV Analyst Ratings
0
Buy
2
Hold
1
Sell
INNV Price Target Range
Low
$5.00
Average
$5.00
High
$5.00
Current: $5.03
Latest INNV Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for INNV.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Sep 18, 2025 | JP Morgan | Benjamin Rossi | Underweight | Assumes | $5.00 |
| Dec 17, 2024 | JP Morgan | Lisa Gill | Underweight | Downgrade | $5.00 |
| Oct 11, 2024 | Keybanc | Matthew Gillmor | Sector Weight | Initiates | $N/A |
| Mar 13, 2024 | JP Morgan | Lisa Gill | Neutral | Maintains | $6.00 |
| Feb 8, 2024 | Goldman Sachs | Jamie Perse | Neutral | Maintains | $7.00 |
| Feb 15, 2023 | Goldman Sachs | Jamie Perse | Neutral | Maintains | $9.00 |
| Feb 8, 2023 | JP Morgan | Lisa Gill | Neutral | Maintains | $8.00 |
| Nov 23, 2022 | Goldman Sachs | Jamie Perse | Neutral | Maintains | $8.00 |
| Nov 16, 2022 | Citigroup | Jason Cassorla | Neutral | Maintains | $8.00 |
| Sep 15, 2022 | Barclays | Sarah James | Equal-Weight | Maintains | $5.00 |
| May 16, 2022 | Baird | Vikram Kesavabhotla | Neutral | Downgrade | $5.00 |
| May 11, 2022 | Piper Sandler | Jeff Garro | Underweight | Maintains | $3.90 |
| Apr 20, 2022 | Piper Sandler | Jeff Garro | Underweight | Downgrade | $5.00 |
| Dec 28, 2021 | Goldman Sachs | Jamie Perse | Neutral | Downgrade | $4.00 |
| Dec 27, 2021 | Barclays | Sarah James | Equal-Weight | Downgrade | $6.50 |
| Dec 17, 2021 | JP Morgan | Neutral | Initiates | $N/A | |
| Sep 29, 2021 | Citigroup | Neutral | Downgrade | $N/A | |
| Sep 22, 2021 | William Blair | Market Perform | Downgrade | $N/A | |
| Sep 10, 2021 | Cowen & Co. | Market Perform | Initiates | $N/A | |
| Aug 12, 2021 | Barclays | Steve Valiquette | Overweight | Upgrade | $19.00 |
InnovAge Holding Corp. (INNV) Competitors
The following stocks are similar to Innovus Pharmaceuticals based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
INNV
Innovus Pharma
mkt cap
682.48M
InnovAge Holding Corp. (INNV) Financial Data
Valuation Metrics
Market Cap
$682.48M
Enterprise Value
$701.92M
P/E Ratio
N/A
PEG Ratio
62.9x
Price/Sales
0.8x
Growth & Margins
Revenue Growth (YoY)
+15.1%
Gross Margin
+21.8%
Operating Margin
+3.6%
Net Margin
-2.0%
EPS Growth
+15.1%
Financial Health
Cash/Price Ratio
+16.0%
Current Ratio
1.2x
Debt/Equity
35.6x
ROE
-7.8%
ROA
+0.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
InnovAge Holding Corp. (INNV) Business Model
About InnovAge Holding Corp.
What They Do
Provides comprehensive healthcare solutions for seniors.
Business Model
InnovAge Holding Corp. operates primarily through the Program of All-Inclusive Care for the Elderly (PACE), which delivers integrated medical and social services to seniors. The company generates revenue by coordinating care and services for older adults, enhancing their quality of life while reducing reliance on costly hospital and nursing home admissions.
Additional Information
Headquartered in Denver, Colorado, InnovAge is expanding its operations across the United States to meet the growing demand for senior care services, emphasizing fiscal responsibility and sustainability in its healthcare delivery model.
Company Information
Sector
Healthcare
Industry
Medical Care Facilities
Employees
2,440
CEO
Mr. Patrick Blair
Country
United States
IPO Year
2020
Website
www.innovage.comInnovAge Holding Corp. (INNV) Latest News & Analysis
Latest News
InnovAge and Tampa General Hospital Celebrate Partnership of Senior Care in Grand Re-Opening
26 days ago
Quick Summary
InnovAge Holding Corp. and Tampa General Hospital have announced a joint venture to enhance access to PACE senior care services in the Tampa Bay area.
Why It Matters
The joint venture between InnovAge and Tampa General Hospital enhances PACE service availability, potentially increasing revenue and market share for InnovAge in the growing senior care sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
InnovAge Holding Corp. (INNV) will host its Q1 2026 earnings call on November 4, 2025, at 5:00 PM EST, featuring key executives including the CEO and CFO.
Why It Matters
The earnings call indicates upcoming financial performance insights, which can influence stock valuation and investor sentiment regarding InnovAge Holding Corp.'s future prospects.
Source: Seeking Alpha
Market Sentiment:
Neutral
InnovAge Announces Financial Results for the Fiscal First Quarter Ended September 30, 2025
1 month ago
Quick Summary
InnovAge Holding Corp. reported strong financial results for Q1 fiscal 2026, ending September 30, 2025, focusing on healthcare programs for frail seniors.
Why It Matters
Strong financial results from InnovAge for Q1 2026 signal business growth and stability, potentially boosting investor confidence and impacting stock performance positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
InnovAge Holding Corp. (INNV) reported Q3 earnings of $0.06 per share, exceeding the Zacks estimate of $0.01 and improving from a loss of $0.04 per share a year prior.
Why It Matters
InnovAge's earnings beat expectations and show a year-over-year improvement, indicating financial stability and potential growth, which could boost investor confidence and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
InnovAge Holding Corp. appointed Dr. Paul Taheri as Chief Medical Officer, effective November 3, 2025. He has over 30 years of healthcare leadership experience.
Why It Matters
The appointment of Dr. Paul Taheri as CMO may enhance InnovAge's strategic direction and operational efficiency, potentially impacting future growth and investor confidence in the company.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Top 3 Earnings Acceleration Buys for November
1 month ago
Quick Summary
Groupon, BriaCell Therapeutics, and InnovAge are experiencing accelerating earnings momentum as November's market optimism builds.
Why It Matters
Accelerating earnings momentum in Groupon, BriaCell Therapeutics, and InnovAge signals potential growth and profitability, attracting investor interest as market optimism builds.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About INNV Stock
What is InnovAge Holding Corp.'s (INNV) stock forecast for 2026?
Based on our analysis of 10 Wall Street analysts, InnovAge Holding Corp. (INNV) has a median price target of $5.00. The highest price target is $5.00 and the lowest is $5.00.
Is INNV stock a good investment in 2026?
According to current analyst ratings, INNV has 0 Buy ratings, 2 Hold ratings, and 1 Sell ratings. The stock is currently trading at $5.03. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for INNV stock?
Wall Street analysts predict INNV stock could reach $5.00 in the next 12 months. This represents a -0.6% decrease from the current price of $5.03. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is InnovAge Holding Corp.'s business model?
InnovAge Holding Corp. operates primarily through the Program of All-Inclusive Care for the Elderly (PACE), which delivers integrated medical and social services to seniors. The company generates revenue by coordinating care and services for older adults, enhancing their quality of life while reducing reliance on costly hospital and nursing home admissions.
What is the highest forecasted price for INNV InnovAge Holding Corp.?
The highest price target for INNV is $5.00 from Benjamin Rossi at JP Morgan, which represents a -0.6% decrease from the current price of $5.03.
What is the lowest forecasted price for INNV InnovAge Holding Corp.?
The lowest price target for INNV is $5.00 from Benjamin Rossi at JP Morgan, which represents a -0.6% decrease from the current price of $5.03.
What is the overall INNV consensus from analysts for InnovAge Holding Corp.?
The overall analyst consensus for INNV is neutral. Out of 10 Wall Street analysts, 0 rate it as Buy, 2 as Hold, and 1 as Sell, with a median price target of $5.00.
How accurate are INNV stock price projections?
Stock price projections, including those for InnovAge Holding Corp., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 5:09 PM UTC